Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Blood

Volumn 127, Issue 10, 2016, Pages 1325-1335

  Chachoua, Ilyas ^a   Pecquet, Christian ^a   El Khoury, Mira ^b,c   Nivarthi, Harini ^d   Albu, Roxana Irina ^a   Marty, Caroline ^b,c   Gryshkova, Vitalina ^a   Defour, Jean Philippe ^a   Vertenoeil, Gäelle ^a   Ngo, Anna ^e   Koay, Ann ^e   Raslova, Hana ^b,c   Courtoy, Pierre J ^a   Choong, Meng Ling ^e   Plo, Isabelle ^b,c   Vainchenker, William ^b,c   Kralovics, Robert ^d   Constantinescu, Stefan N ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Universite Paris Sud   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e Agency for Science   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; DNA; GLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; THROMBOPOIETIN RECEPTOR; CALRETICULIN, HUMAN; CYSTEINE AND GLYCINE-RICH PROTEIN 3; JAK2 PROTEIN, MOUSE; LIM PROTEIN; MPL PROTEIN, HUMAN; MUSCLE PROTEIN; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DELETION MUTANT; GENE ACTIVATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; WILD TYPE; ANIMAL; GENETICS; GLYCOSYLATION; HEMATOLOGIC DISEASE; METABOLISM; MOUSE; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CALRETICULIN; CELL LINE, TUMOR; GLYCOSYLATION; HEMATOLOGIC NEOPLASMS; JANUS KINASE 2; LIM DOMAIN PROTEINS; MICE; MUSCLE PROTEINS; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84960851640     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-681932     Document Type: Article

References (45)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114(5):937-951.
2. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601-2613.
3. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714-3719.
4. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
7. Marty C, Harini N, Pecquet C, et al. Calr mutants retroviral mouse models lead to a myeloproliferative neoplasm mimicking an essential thrombocythemia progressing to a myelofibrosis [abstract]. Blood. 2014;124(21). Abstract 157.
8. Marty C, Pecquet C, Nivarthi H, et al. Expression of calreticulin mutants in mice induce a MPL-dependent thrombocytosis progressing to myelofibrosis for the type I mutant [published online ahead of print November 25, 2015]. Blood. doi:10.1182/blood-2015-11-679571.
9. Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution. Leukemia. 2015;29(1):249-252.
10. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms [published online ahead of print October 9, 2015]. Leukemia. 2015. doi: 10.1038/leu.2015.277.
11. Staerk J, Defour JP, Pecquet C, et al. Orientationspecific signalling by thrombopoietin receptor dimers. EMBO J. 2011;30(21):4398-4413.
12. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280(29): 27251-27261.
13. Albu RI, Constantinescu SN. Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. Front Endocrinol (Lausanne). 2011;2:71.
14. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: Implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010;8(9):e1000476.
15. Pang SF, Li XK, Zhang Q, Yang F, Xu P. Interference RNA (RNAi)-based silencing of endogenous thrombopoietin receptor (Mpl) in Dami cells resulted in decreased hNUDCmediated megakaryocyte proliferation and differentiation. Exp Cell Res. 2009;315(20): 3563-3573.
16. da Costa Reis Monte-Mór B, Plo I, da Cunha AF, et al. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. Leukemia. 2009;23(1):144-152.
17. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997; 17(2):695-706.
18. Mesaeli N, Nakamura K, Zvaritch E, et al. Calreticulin is essential for cardiac development. J Cell Biol. 1999;144(5):857-868.
19. Wood TJ, Sliva D, Lobie PE, et al. Specificity of transcription enhancement via the STAT responsive element in the serine protease inhibitor 2.1 promoter. Mol Cell Endocrinol. 1997; 130(1-2):69-81.
20. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythromegakaryocytic progenitor in human bone marrow. Blood. 1996;88(4):1284-1296.
21. Remy I, Michnick SW. A highly sensitive proteinprotein interaction assay based on Gaussia luciferase. Nat Methods. 2006;3(12):977-979.
22. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110(7):2540-2545.
23. Courtoy PJ. Analytical subcellular fractionation of endosomal compartments in rat hepatocytes. Subcell Biochem. 1993;19:29-68.
24. Choong ML, Pecquet C, Pendharkar V, et al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med. 2013;17(11): 1397-1409.
25. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
26. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calciumbuffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417(3):651-666.
27. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8(6): 1327-1338.
28. Tong W, Sulahian R, Gross AW, Hendon N, Lodish HF, Huang LJ. The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and-independent mechanisms. J Biol Chem. 2006; 281(50):38930-38940.
29. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem. 1999; 274(19):13480-13484.
30. Kollmann K, Nangalia J, Warsch W, et al. MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia. 2015;29(2):494-497.
31. Guglielmelli P, Rotunno G, Bogani C, et al. Ruxolitinib is an effective treatment for CALRpositive patients with myelofibrosis [published online ahead of print August 25, 2015]. Br J Haematol. doi:10.1111/bjh.13644.
32. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790-797.
33. Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014;370(12):1168-1169.
34. Bartalucci N, Tozzi L, Bogani C, et al. Cotargeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. 2013;17(11):1385-1396.
35. Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 2): S307-S309.
36. Chen WM, Yu B, Zhang Q, Xu P. Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC). J Biol Chem. 2010;285(34): 26697-26709.
37. Kapoor M, Ellgaard L, Gopalakrishnapai J, et al. Mutational analysis provides molecular insight into the carbohydrate-binding region of calreticulin: Pivotal roles of tyrosine-109 and aspartate-135 in carbohydrate recognition. Biochemistry. 2004;43(1):97-106.
38. Mondet J, Park JH, Menard A, et al. Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia. Haematologica. 2015;100(5):e176-e178.
39. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12(5): 1239-1250.
40. Matthews EE, Thévenin D, Rogers JM, et al. Thrombopoietin receptor activation: Transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011;25(7): 2234-2244.
41. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: Differences in phenotype and prognostic impact. Leukemia. 2014;28(7): 1568-1570.
42. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol. 2014; 89(8):E121-E124.
43. Yoshida H, Kondo M, Ichihashi T, et al. A novel myeloid cell line, Marimo, derived from therapyrelated acute myeloid leukemia during treatment of essential thrombocythemia: Consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet. 1998;100(1):21-24.
44. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123-e133.
45. Lau WW, Hannah R, Green AR, Göttgens B. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood. 2015; 125(10):1679-1681.